Abstract

Efficacy of Ravuconazole in Treatment of Systemic Murine Histoplasmosis K. V. Clemons 1 , 2 , 3 , * , M. Martinez 1 , L. Calderon 1 and D. A. Stevens 1 , 2 , 3 1 California Institute for Medical Research 2 Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center, San Jose, California 95128 3 Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California 94305 ABSTRACT Ravuconazole (RCZ) was evaluated for efficacy in comparison to fluconazole (FCZ) and itraconazole (ITZ) in murine models of disseminated histoplasmosis. All regimens tested prolonged survival ( P < 0.05 to 0.0001). At equivalent doses of 50 mg/kg of body weight, RCZ and ITZ were equally effective and RCZ was more effective than FCZ ( P = 0.02). Clearance of fungal burden from the livers and spleens of mice showed RCZ and ITZ at doses of 50 mg/kg to be efficacious but not curative. These data indicate that RCZ should be studied further.